Announcing a new comms channel is only any good if you then use it and have sufficient content that you’re willing to publish, otherwise it simply provokes more dissent. I do hope they will be reasonably active with this over the coming weeks.
RE: Stake building or short closing?01 Sep 2021 16:13
Geordieexpat, successful rollout of the LFTs would still be amazing but this wouldn't match the value of the therapeutic platforms which could take the business to the 10s of billions in value if they came off. I guess the growing enthusiasm for this is that has become that much closer now and is on the cusp.
Go kip out Doggy. It will all still be there in the morning. The eventual outcome is inevitable, even if it might no be tomorrow. We’re a done deal and just a matter of over the line. Of course we’re a bit shell shocked for the waiting but big things always come in the end. Many thanks to the amazing researchers on our BB who have helped differentiate this stock from all of the rest out there.
Blimey. My first look since early this morn. Get the feeling this is AV6000 for something like this. That would be a global news event in time. Whichever way, so pleased to be bit blue again. Best to all.
RE: IMO Avacta has already missed the boat09 Aug 2021 12:00
Private Ryan, spot on. I think though that if one of those products proves successful it would be one of the biggest medical stories in many a year and considerably higher than a 1B market cap. We are selling the best LFDs and the market is arguably going to grow with ease of use and home testing replacing the current PCR nightmare. I’ve just had to pay £800 for family tests for travel. I remain hugely and ever more excited about the short and medium term.
RE: IMO Avacta has already missed the boat09 Aug 2021 11:35
Respectfully Waggy, that is nonsense. The product is clearly outstanding, is now selling well and with a market that is most likely going to increase with ease of use and home testing around the corner. There’s no blind faith. It remains to be an incredible business with a staggering pipeline in short and medium term. I remain hugely positive about the coming months.
With some despicable competitors and dark vested interests potentially undermining sales opportunities I wouldn’t want to be saying too much about who we’re selling to and what volumes at this stage. Would prefer to have numerous sales channels and good usability reviews all in the bag before we say too much more. It’s happening and that’s all we need to know for a wee while longer. I’m sure sales will flourish dramatically over the coming months.
Anyone know why Doxorubicin is the first? Just interested to know if there’s a particular reason. Also what the next most likely chemos might be, once first trial is done. Doesn’t seem to be any reason why the whole chemo market couldn’t be tackled if it works. Thanks
It's a real opportunity for the diagnostics business, with the best product but underperforming commercially, to be acquired and properly exploited by a stalking acquisitor; an organisation with global reach, that could consolidate the market and supply vast numbers worldwide. It may already be at early stages with initial stake building forays
Aside from the comms howlers from the Avacta board, it’s beyond belief that we see these prices right now. Considering all the ticks are in now and the Covid issue is about to blow up again even worse. I’m glad to have built even more over the last few weeks. I’m not going anywhere, staying for a long time and will not be moved.